Insmed reported Q1 2026 on May 7. The stock dropped 23% on the day and recovered to $118 by May 13, still 42% below the $204 sell-side mean target. The reaction priced one question — discontinuation — and didn't price ARIKAYCE label expansion.

What the filing says

BRINSUPRI's second full quarter: ≈$245M revenue (implied; total INSM ≈$305M with ≈$60M ARIKAYCE base), 44% sequential growth, 90% payer approval, >70% continuation, 5,000+ writers across ≈25% of pulmonologists. Q1 was the last "ready-and-waiting" quarter; Q2 is the first pure-organic-demand test. Management deferred a guidance raise as "premature" but cited positive April data.

ARIKAYCE ENCORE Phase IIIb hit in newly-diagnosed NTM MAC: >80% culture conversion vs ≈30% in the refractory setting. Management committed to H2 2026 sNDA filing. Label expansion claim: TAM 30K refractory → 200K+ newly-dx, $1B+ peak vs current ≈$400M base.

Cash $1.2B, 2027 cash-flow-positive without a raise.

The bear signal management deflected

The most concrete bearish moment in the call was a Q&A exchange. Analyst Gavin Clark-Gartner laid out math: for ≈11,500 patients started by end of Q4 2025, ≈2,500+ implied discontinuations by end of Q1 2026 → 22-25% 6-month discontinuation. Management did not refute, confirm, or walk through the calculation. They deflected to "slightly above" statin benchmark (≈70% continuation at 6 months) and offered a sidebar.

This matters because the launch thesis is mechanical: organic Q2 growth requires new-patient adds to outpace cohort erosion. If true discontinuation is 25%+ and new-start velocity holds, the curve flattens. If it's <20%, the $1B FY guide is conservative. The Q2 2026 10-Q (filed mid-August alongside the print) is the most likely venue for cohort retention disclosure. TVTX Filspari, the closest specialty pharma analog, faced no equivalent analyst pressure — this is INSM-specific.

What the market thinks

Stock at $118 implies bull-case probability ≈31% on a linear $204 (consensus) / $80 (floor) model. Options at Jan 2027 ATM IV 51% (vs realized 70.8%) imply P(stock > $200) ≈ 10%. Sell-side: 21 buys, 0 holds, 0 sells; Wells Fargo and RBC reiterated $160-$205 post-call. The tape and the consensus model are 50-70% apart.

Why the gap exists

ENCORE is buried in narrative. A cross-corpus scan of 10,612 Q1 2026 earnings transcripts found zero competitor mentions of newly-dx NTM MAC outside the INSM call itself. AN2 Therapeutics confirmed in their 10-K (filed 2026-03-17) and 10-Q (2026-05-11) that epetraborole has been pivoted entirely out of NTM MAC into polycythemia vera and Chagas. No public competitor is at Phase 2 or Phase 3 in this indication. The call ran 90 minutes; ENCORE got ≈6.

This is "currently uncontested at Phase 3" — not the same thing as no commercial threat. The newly-dx 200K population today receives off-label generic combinations (azithromycin / ethambutol / rifampin). ENCORE will need to displace a low-cost SOC with an inhaled liposomal regimen at branded pricing. The Phase IIIb superiority data is the displacement argument. Sell-side $204 mean target presumably models this displacement curve; whether the market is willing to underwrite it is the open question.

MFN drag dominates the narrative. Every peer in the cohort (MDGL, GERN, MLYS, SRRK, ZYME, JAZZ, RPRX, plus mega-cap pharma) flagged MFN as unresolved in Q1 2026 calls. SRRK is exploring Germany-first launches; ZYME priced MFN into a royalty deal. The cohort is rerouting around the policy, not waiting it out. The drag is real and structural. The $1B FY BRINSUPRI guide implicitly assumes minimal ex-US contribution given the pause; whether US momentum alone delivers the number is what Q2 prints test.

Risks (ranked)

1. Discontinuation rate confirmed ≥25%. Mechanical breakage of the launch curve; Q2 sequential decline follows; FY guide cuts. The deflected Q&A and missing 10-Q cohort disclosure are why this is unresolved.
2. Generic SOC sticky in newly-dx. ENCORE displacement curve slower than modeled; peak <$1B; ARIKAYCE expansion becomes a long-tail story not a 2027-2028 catalyst.
3. MFN structural through 2028. Caps ex-US contribution; Chinese biosimilars fill the European vacuum.
4. ENCORE CRL or restrictive label. Low base rate given FDA-agreed surrogate and clean trial, but possible.
5. Boehringer Ingelheim BI 1291583 Phase 3. Readout 2027-2028; private and currently unverifiable.

Catalysts

• Q2 2026 earnings, ~Aug 5-7. Hard binary on launch trajectory; 10-Q discontinuation disclosure.
• ARIKAYCE ENCORE sNDA filing, H2 2026. 8-K confirms catalyst is live; priority review (orphan indication) compresses approval to H1 2027 vs Q3 2027 standard.
• TPIP PAH OLE 24-month data, Q3 2026. Pipeline de-risking.
• PDUFA acceptance + designation, late 2026 / Q1 2027.
• MFN policy resolution. Open-ended; no near-term peer signals.

What would change our mind

• 10-Q discloses 6-month discontinuation rate ≥25% — patient retention concern validated
• Q2 sequential revenue decline >5% — launch thesis cracks
• ENCORE filing delays past Q1 2027 — Jan 2027 options window misses
• FDA AdCom requested — P(ENCORE approval) drops from ≈78% to ≈55%
• Insider P-code (open-market purchase) by a Section 16 officer — strong corroboration (currently absent; CEO selling has been Form 4 code M exercise-driven, not P)

Forward scenario grid

Joint outcomes across BRINSUPRI ramp and ENCORE approval, independence assumed (likely overstates tails — both legs are positively correlated through commercial execution):

Probability-weighted EV: +30 to +45% over 9-12 months (range reflects independence assumption sensitivity). Target intrinsic value: $155-170.

The state targets depend on the floor assumption. A $95 floor (cash $1.2B + ARIKAYCE refractory at 4-5x revenue + TPIP optionality) shifts the bear-state targets upward by $10-15 each, compressing implied bull probability from 30.6% to ≈21% and the edge accordingly. The directional case survives the sensitivity; the magnitude does not.

Idio audit

140 trading days post-launch (Oct 2025 — pre-call): idiosyncratic variance 82.3% (above 75% target), β_XBI 0.90, β_SPY -0.76. Style factors (momentum, size, value, quality, duration) all insignificant. The stock is a clean two-factor name (market + biotech sector + idiosyncratic); the thesis lives in the idio share.

Evidence